ACVIM Lyme borreliosis

123456789101112131415161718192021222324252627282930313233343536373839404142434445
Across
  1. 4. : Type of antibody assay recommended for annual screening.
  2. 8. : Descriptor preceding nephropathy in severe renal disease.
  3. 9. : Finding that should always be screened for in every seropositive dog.
  4. 12. : European breed with an unusually high seroprevalence.
  5. 13. : Bacterial genus responsible for Lyme borreliosis.
  6. 15. : Outer surface protein upregulated during tick feeding and mammalian infection.
  7. 17. : Tick preventive that repels and prevents attachment but must never be used in cats.
  8. 18. : Injectable antimicrobial shown to be comparable to doxycycline in experimental infection.
  9. 19. : Preferred immunosuppressive drug for severe immune-complex glomerulonephritis.
  10. 21. : Development of detectable antibodies after exposure.
  11. 23. : Preventive measure unanimously recommended regardless of vaccination status.
  12. 24. : Histologic lesion described at experimental tick bite sites.
  13. 27. : Most common clinical manifestation of Lyme borreliosis in dogs.
  14. 29. : Outer surface protein expressed in the tick midgut before transmission.
  15. 30. : Renal lesion associated with immune-complex deposition.
  16. 31. : Common systemic clinical sign accompanying Lyme arthritis.
  17. 35. : Tetracycline considered an alternative to doxycycline.
  18. 37. : Isoxazoline effective against Ixodes transmission.
  19. 39. : Acceptable alternative antimicrobial for Lyme borreliosis.
  20. 40. : Species responsible for canine Lyme disease in North America.
  21. 41. : Severe renal manifestation putatively associated with Lyme borreliosis.
  22. 44. : Principal Ixodes vector in Europe.
  23. 45. : Typical presenting clinical sign in affected dogs.
Down
  1. 1. : Mild enlargement of lymph nodes may accompany acute disease.
  2. 2. : Characteristic of most healthy seropositive dogs.
  3. 3. : Type of C6 assay whose routine use remains controversial.
  4. 5. : Type of pathogen transmission occurring between tick life stages.
  5. 6. : Tick genus responsible for transmitting Borrelia burgdorferi.
  6. 7. : Possible explanation for recurrence after successful treatment.
  7. 10. : Mechanism believed to contribute to Lyme nephritis.
  8. 11. : Main North American Ixodes vector.
  9. 12. : Possible coinfection that may complicate interpretation of Lyme disease.
  10. 14. : Breed group overrepresented among dogs with suspected Lyme nephritis.
  11. 16. : Corticosteroid that may be added for rapidly progressive glomerular disease.
  12. 18. : Peptide used in serologic testing to detect natural exposure to Borrelia.
  13. 20. : General term for products used to prevent tick infestation.
  14. 22. : Variable major protein-like sequence expressed; antigen used in modern serologic assays.
  15. 25. : Tick-borne coinfection commonly covered by doxycycline.
  16. 26. : Clinical recurrence that requires reconsideration of differential diagnoses.
  17. 28. : First-line antimicrobial recommended for canine Lyme arthritis because it also covers common tick-borne coinfections.
  18. 32. : Important explanation for persistent or atypical clinical signs.
  19. 33. : Another oral isoxazoline used for tick prevention.
  20. 34. : Another important tick-borne pathogen included in differential diagnoses.
  21. 36. : Topic for which the panel did not reach full consensus.
  22. 38. : Describes a dog with detectable antibodies against Borrelia.
  23. 42. : Histologic lesion observed experimentally after infection.
  24. 43. : Isoxazoline that rapidly kills attached ticks.